Nippon Chemiphar

4539.TPharmaceutical

Key numbers · FY ended 2026-03

Revenue¥33.1bn+1.6% YoY Operating income¥179m-70.5% YoY Net income (owners)¥198m-32.7% YoY Total assets¥50.0bn+0.3% YoY EPS (basic)¥54.81-32.9% YoY

Full financial history and reports →

Stock price4539 · View chart ↗

Open the price chart on TradingView.

Latest filings

Wed, Aug 5 · JST1 filing

11:035% STAKENippon Chemiphar · Japan Sopharcim CO., LTD + 2 joint holders · 20.46% → 21.48%+1.02pp

Fri, Dec 5 · JST2 filings

09:425% STAKENippon Chemiphar · Yamaguchi Scientific Promotion Public Interest Incorporated Foundation · 7.04%new 7.04%09:385% STAKENippon Chemiphar · Japan Sopharcim CO., LTD + 2 joint holders · 27.49% → 20.46%−7.03pp

Fri, Aug 8 · JST1 filing

11:025% STAKENippon Chemiphar · Japan Sopharcim CO., LTD + 2 joint holders · 24.65% → 27.49%+2.84pp

All filings →

Major holders (5%+) · 4

Holder	Stake	Change	Filed
Japan Sopharcim CO., LTD	21.48%	+1.02pp	2026-08-05
Yamaguchi Scientific Promotion Public Interest Incorporated Foundation	7.04%	—	2025-12-05
Toshima Pharmaceutical Co., Ltd.	5.68%	0.00pp	2025-08-08
Kazushiro Yamaguchi	5.07%	+0.01pp	2025-08-08

Each holder's own ratio from its most recent large-shareholding report.